[Breast Cancer: Targets and Therapy] This review summarizes current knowledge of predictors and prognostic biomarkers of this rare and highly aggressive subtype of breast cancer.
The ctDNA level at baseline was associated with response, PFS, and OS with pembrolizumab in patients with different tumor types.
This study showed that MPN is more aggressive in men vs women and explored whether sex differences in the genomic landscape of MPN could explain this difference.
[Journal of Hepatocellular Carcinoma] In this review, the authors discuss the use of imaging techniques and radiological biomarkers to monitor treatment response in patients with advanced HCC undergoing antiangiogenic therapy, a key to decisions on whether to continue treatment or initiate second-line therapy.
Although some red blood cell-related parameters used in the diagnosis of PV may be misleading in the setting of iron-deficiency, RBC count may be an effective biomarker for PV when combined with ESR.
Palliative care and end-of-life needs were not addressed for approximately 40% of simulated patients who would have been eligible for this approach.
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
A sudden increase of serum-free light chains was associated with treatment-induced tumor lysis syndrome in multiple myeloma, suggesting a possible risk factor.
High prevalence of pathogenic/likely pathogenic variants supports wider testing.
A systematic review of studies sought to determine the likelihood of myeloproliferative neoplasm subtypes based on patients’ genetic alterations.
